In 2022, over 600,000 people across the world were diagnosed with bladder cancer, a 7.1% increase from 2020, putting their ...

Accredited Social Health Activists (ASHAs) have surveyed communities to identify eligible individuals, finalising the list ...

Today, bacillus Calmette–Guerin (BCG) vaccine is a well-established treatment for human bladder cancer that is arguably superior to intravesical chemotherapy for superficial disease and is ...

There may be an effective new treatment for people with bladder cancer that doesn't respond to a frontline therapy.

Shares of Protara Therapeutics Inc. skyrocketed over 100% on Thursday afternoon, reaching levels last seen in January 2022 ...

BOSTON & MONTREAL, December 19, 2024--enGene Holdings Inc. (Nasdaq: ENGN, or "enGene" or the "Company"), a clinical-stage ...

unresponsive to Bacillus Calmette Guerin (BCG). The trial demonstrated that 74.5% of patients (82 out of 110) achieved a complete response (CR) at any time after receiving treatment with ...

The trial is assessing intravesical TARA-002, the Company’s investigational cell-based therapy, in high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) patients with carcinoma in situ or CIS (± Ta/T1) ...

In addition, the company develops TLD-1433, which is in Phase II clinical trial for the treatment of Bacillus Calmette Guérin - Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ.